Malaria vaccine shows postitive effectiveness in tests

Advanced Life Sciences Holdings recently announced that studies testing the effectiveness of its drug Restanza, an oral antibiotic used to combat a type of Plasmodium that cause malaria, have been positive.

The company’s in vitro study compared Restanza to azithromycin. According to the company's report, Restanza showed a two to ten-fold greater effectiveness compared to azithromycin against Plasmodium falciparum.

The in vivo section of the study concluded that Restanza was 100 percent effective in treating mice infected with Plasmodium berghei. It was three times more potent than azithromycin at half the dose.

Advanced Life Sciences chairman and CEO Michael Flavin said he is pleased with the results of the study.

“These promising data underscore Restanza's demonstrated broad activity against multiple disease-causing infectious agents, including Streptococcus pneummoniae, a variety of pathogens that represent potential bioterror threats and, now, the species of parasites that cause malaria,” Flavin said. “We believe that Restanza represents a promising pipeline in and of itself, and we intend to continue to explore the wide range of its therapeutic potential. Our goal is to generate a portfolio of indications that we can develop and commercialize either on our own or in partnership with pharmaceutical companies with established anti-infective franchises.”

Malaria is a parasitic disease that is characterized by high fevers, shaking chills, flu-like symptoms and anemia and requires hospitalization. It is typically caused by a parasite that is transmitted from one human to another by the bite of infected mosquitoes.